Granules India delivered a record FY26 — 6 consecutive quarters of sequential revenue growth, EBITDA margin +100 bps, and the peptide CDMO business (Ascelis) turning EBITDA positive. The US ranking jump from 74th to 27th in 5 years and 4th in controlled substances reflects a genuine competitive position upgrade. FY27 capex of ₹600 crore funds the next growth phase — FDA re-inspection of Gagillapur is the key timing risk. Good sentiment, high confidence.
Headline Numbers
| Metric | FY26 | Q4 FY26 | Notes |
|---|---|---|---|
| Revenue | ₹5,366 crore | ₹1,471 crore | Record; 6 consecutive sequential quarters |
| EBITDA | ₹1,185 crore | — | +100 bps margin expansion |
| PAT | ₹595 crore | — | — |
| Net Debt/EBITDA | 0.34x | — | Lean balance sheet |
| R&D Spend | 5.3% of sales | — | Above-average for generics |
| US Generic Ranking | 27th | — | From 74th in FY21 |
| US Controlled Substance Rank | 4th | — | High-barrier segment |
| Ascelis Q4 Revenue | — | ₹70 crore | Doubled from ₹33 crore Q3 |
| FY27 Capex | ~₹600 crore | — | Complex generics + CDMO |
What Drove the Results
- US ranking 74th → 27th in 5 years is the strategic transformation: Granules moved from being a mid-tier bulk pharma supplier to a top-30 US generic pharmaceutical company. This ranking is based on prescription volume and market share in the US generic market. The 4th rank in controlled substances (pain management, CNS drugs) is a particularly high-barrier position — few Indian manufacturers can handle these products at scale and with US FDA compliance.
- Ascelis (peptide CDMO) turning EBITDA positive is the margin catalyst: Ascelis revenue doubled QoQ in Q4 (₹33 crore → ₹70 crore) and turned EBITDA positive. Peptides are the highest-value, highest-barrier segment in pharma manufacturing. As GLP-1 drugs (semaglutide-type weight-loss and diabetes treatments) create global peptide demand, Ascelis is positioned as a CDMO partner for innovator companies needing peptide APIs and formulations.
- 6 consecutive quarters of sequential revenue growth confirms execution: Revenue growth every quarter for 6 consecutive quarters shows that the business is not lumpy or project-dependent — it is systematically scaling. This is unusual in pharma, where quarterly revenue can swing significantly.
- 100 bps EBITDA margin expansion — mix-driven: The margin improvement reflects the shift toward complex generics (higher margins than simple generics) and the early-stage contribution from Ascelis. R&D at 5.3% of sales is above-industry and is the investment behind this margin improvement — complex molecule development takes 3-5 years before commercialisation.
- Gagillapur FDA re-inspection is the timing risk: Granules' Gagillapur facility received a 483 observation. FDA re-inspection timing is uncertain and outside Granules' control. Until cleared, some product launches from this facility may be delayed. Management has prioritised quality remediation and is fully prepared for re-inspection — the constraint is FDA scheduling.
What Management Said
Management was specific on the transformation story and honest on the Gagillapur constraint. On Ascelis: "Peptide CDMO is now EBITDA positive — the turnaround is complete. Q4 revenue doubled. We see FY27 as a year of further scaling." On US ranking: "27th from 74th in 5 years is the result of consistent filing and launch execution — we're not done." On Gagillapur: "Regulatory timelines [FDA re-inspection] are the primary near-term constraint. We are fully prepared — the timing is the FDA's." On capex: "₹600 crore in FY27 for complex generics and CDMO scale-up. Net debt/EBITDA at 0.34x gives us headroom."
Key Tailwinds and Risks
Tailwinds:
- US ranking 27th (74th in FY21) — top-30 position with further improvement runway
- 4th in US controlled substances — high-barrier, high-margin segment
- Ascelis peptide CDMO EBITDA positive and scaling — GLP-1 demand tailwind
- Net debt/EBITDA 0.34x — headroom for ₹600 crore FY27 capex without balance sheet stress
- 6 consecutive quarters of sequential revenue growth — execution consistency confirmed
Risks:
- Gagillapur FDA re-inspection timing — outside Granules' control; delays = product launch delays
- Rising raw material, packaging, and freight costs from West Asia tensions
- Ascelis (Senn Chemicals) integration still early-stage — execution risk in CDMO scale-up
- Complex generic development is capital and time-intensive — R&D at 5.3% limits near-term FCF
- US generic price erosion (structural) — requires continuous product complexity upgrade to maintain margins
StockMirror AI Signal Summary
| Signal | Reading |
|---|---|
| Overall Sentiment | Good |
| Management Confidence | High |
| Prepared Remarks | Good — record performance, US ranking milestones, Ascelis turnaround |
| Q&A Sentiment | Good — direct on Gagillapur constraint, CDMO scaling |
| Revenue Growth | On track — 6 consecutive sequential growth quarters; record FY26 |
| Margin Direction | Expanding — EBITDA +100 bps; Ascelis EBITDA positive accelerates mix improvement |
| Earnings Quality | Clean — no significant one-time items; 0.34x net debt/EBITDA |
Track Granules India's full AI signal breakdown — US market share progress, Ascelis CDMO ramp, and FDA inspection status — at Granules India's earnings page.
Key Takeaways
- FY26 record: revenue ₹5,366 crore; EBITDA margin +100 bps; PAT ₹595 crore
- US generic ranking: 74th (FY21) → 27th (FY26); 4th in controlled substances
- 6 consecutive quarters of sequential revenue growth — execution confirmed
- Ascelis peptide CDMO: EBITDA positive, Q4 revenue doubled (₹33 cr → ₹70 cr)
- FY27 capex ₹600 crore; net debt/EBITDA 0.34x — balance sheet headroom available
- Key risk: Gagillapur FDA re-inspection timing (uncertain, outside management's control)
Frequently Asked Questions
What was Granules India's revenue and EBITDA margin in FY26? Granules India reported record FY26 revenue of approximately ₹5,366 crore with EBITDA of approximately ₹1,185 crore (margin +100 bps YoY). PAT was approximately ₹595 crore. Net debt/EBITDA stood at a lean 0.34x, providing significant balance sheet headroom for the planned ₹600 crore FY27 capex.
How did Granules India improve from 74th to 27th in the US generic market? Granules India systematically filed and launched new generic products in the US over 5 years — each new ANDA (Abbreviated New Drug Application) approval and commercial launch builds market share. The jump from 74th to 27th reflects both volume growth and strategic focus on high-value segments (controlled substances, complex generics). The 4th rank in controlled substances required additional US DEA licensing and manufacturing capability — a high-barrier position that fewer Indian companies hold.
What is the Gagillapur FDA inspection risk for Granules India? Granules India's Gagillapur manufacturing facility received a US FDA Form 483 observation (a list of concerns found during inspection). The facility requires a re-inspection before FDA will approve new product applications from Gagillapur. Re-inspection timing is set by FDA's schedule — Granules cannot accelerate it. Until clearance, some product launches are delayed. Management states the facility is fully remediated and prepared. This is a timing risk, not a quality crisis.
What is peptide CDMO and why is Ascelis significant for Granules? Peptide CDMO means manufacturing custom peptide APIs (Active Pharmaceutical Ingredients) for drug companies. Peptides are complex molecules used in GLP-1 drugs (like semaglutide/Ozempic for weight loss and diabetes), oncology, and other therapeutic areas. Ascelis, acquired as Senn Chemicals, gives Granules an entry into this high-margin, high-barrier segment. Turning EBITDA positive in FY26 (with Q4 revenue doubling to ₹70 crore) confirms the acquisition thesis is working.
Related: Laurus Labs FY26 · Navin Fluorine Q4 FY26
Disclaimer: This article is for informational purposes only and does not constitute investment advice. StockMirror's AI analysis is based on publicly available earnings transcripts and BSE/NSE filings. Please consult a SEBI-registered financial advisor before making investment decisions.